Sat, Sep 20, 2014, 10:42 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ADVENTRX Pharmaceuticals, Inc. Message Board

  • yags_2001 yags_2001 Dec 15, 2011 11:16 AM Flag

    Vista Partners....$3.50? LOL!!

    Look, I know you folks think I went rogue on you, but did you read the PR by Vista Parnters? Seriously? Did you read it? They are somehow trying to compare apples to oranges here with really no basis of factual quantitative fair market value analysis......yeah, a private company is in with the deal with Pfizer on a sickle cell drug, but I like how Vista just pull that $340mm number out of the hat....like as if that is suppose to represent some kind of fair value for ANX's potential here.....read below:

    "This would seem to indicate that the Company is currently being given little to no value for its two, fully funded late stage clinical candidates: ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis; ANX-514, a detergent-free reformulation of the blockbuster drug Taxotere." Mr. Silver concludes, "As reported by theflyonthewall.com on October 11, 2011 , GlycoMimetics (private) entered into an exclusive worldwide licensing agreement with Pfizer for their investigational compound GMI-1070 currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease. The potential value of the agreement for GlycoMimetics is approximately $340M , including an upfront payment as well as development, regulatory and commercial milestones. The Pfizer deal with Glycomimetics provides considerable validation for sickle cell disease and would seem to provide a benchmark for which to base value of ANX-188, which ADVENTRX has stated, will begin a Phase 3 trial in 2012."

    BENCHMARK???? ANX has a CEO that can't even tie his shoes and these clowns are suggesting something that Pfizer is involved in is comparatory to ANX.....You have got to be chitting me!.....its one thing to bring Pfizer's name into the picture, its another to try to compare ANX to it..LOL!

    Look, if ANX fires Culley and hires someone from Pfizer that has taken a drug through the FDA approval process then ......HEY! I'm with ya VISTA PARTNERS!!!...until then, any comparison of the incompetence that is guiding ANX to a well established Pharma like Pfizer is absurd.....

    obviously the market feels the same way about the $3.50 target price today...up 1 to 2 cents.....I might sell some here just to get the price to drop.........Culley must be sweating this out to get his buds at Vista to release a bogus article like this.....unfckinbelievable!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I agree. it absolutely stinks.

      • 2 Replies to johnwatson68
      • watson, I'm so disgusted with this company that at this point....I'm on the verge of giving in and selling my shares.....I'm trying to convince myself to hold it together and stay positive...but with what appears to be a vote of confidence for Culley(elected/selected to the BOD),this makes absolutely NO SENSE....unless he is being rewarded for making the shorts a TON of money...how else can this be perceived? He added NEGATIVE VALUE to the current shareholders.....woeful performance imho....

      • It doesn't just stink, it should be criminal. How many shorts do you think covered over the past 4 weeks are benefiting from this well timed pump? Why do you always see these "price targets" come out after bad news has already rocked the stock and most folks have already sold.

        It exists to benefit the shorts who have covered after bad news. Any longs who bought the lows also benefit, but they usually never sell, so they just end up watching the meager gains slip away anyway.

        Just flat out criminal.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AutoZone, Inc.
NYSEFri, Sep 19, 2014 4:02 PM EDT
Dresser-Rand Group Inc.
NYSEFri, Sep 19, 2014 4:04 PM EDT